David Kellner, MD: GLP-1 stands for glucagon-like peptide-1, which is a complicated sounding name, but basically it's a hormone that your body naturally releases after you eat
No patients discontinued or interrupted study drugs due to AEs
Other research has found that GLP-1 receptor agonists did not increase suicide risk and that semaglutide may be linked to lower suicidal ideation risk than other obesity or diabetes drugs
You will have better control over your condition if you take these drugs and change your way of life
First approved for type 2 diabetes as Ozempic, the higher-dose Wegovy is intended for chronic weight management, delivering semaglutide at 15-20% of the body weight. It acts on GLP-1 receptors in the pancreas, promoting insulin secretion and reducing glucagon, which regulates blood sugar
These effects contribute to renal protection and may improve cardiac function in T2D patients with cardiovascular risk